Neurim Can't Stop Mylan From Restarting Melatonin Fight
Generic-drug maker Mylan is free to challenge the validity of Israeli pharmaceutical company Neurim's melatonin patent at an upcoming trial after a London judge ruled Monday that it did not run...To view the full article, register now.
Already a subscriber? Click here to view full article